Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Jul 11, 2015 12:19pm
97 Views
Post# 23914386

RE:RE:RE:Other regional deals could follow quickly

RE:RE:RE:Other regional deals could follow quicklySir_Holler.<br /> <br /> The Hepalink deal closure gives access of rvx-208 to 13.4% of the worlds GDP as estimated by the IMF for 2014. This is a $10.4 trillion (USA$) economy so I think there is room for this important drug.<br /> <br /> The approval for phase lll BETonMACE in the EU gives access to 23.9% of the worlds GDP based on IMF 2014 estimates (a $18.5 trillion economy).<br /> <br /> So if, and it is still a possibility, the BoM phlll is approved for DM,CVD,low HDL in the USA that will give access to another 22.5% &nbsp;of the worlds economy or and additional $17.4 trillion GDP (USA$) economy.<br /> <br /> I&#39;m very happy with the EU and the Territories (China, Hong Kong, Taiwan, Macau). These countries are more nimble than the USA and have a sense of urgency.<br /> <br /> The sense of urgency is also accelerated by the business model with Hepalink.<br /> <br /> The FDA will fall into line as results come in from more progressive countries, and, if not, please keep in mind that the USA is only roughly 4% of the worlds population.<br /> <br /> Of course health care costs in the USA are some of the highest costs in the world and yet access to health care lags far behind most developed countries in the world. The implication is that the profits will be huge when rvx-208 finally gets into the USA.<br /> <br /> So I fully agree with you.<br /> <br /> Cheers...I&#39;m off to the lake.<br /> Toinv &nbsp; &nbsp; &nbsp; :)
Bullboard Posts